A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines

<p>Abstract</p> <p>Background</p> <p>In 2001, two hexavalent vaccines were licensed in Italy (Hexavac<sup>®</sup>, Infanrix Hexa<sup>®</sup>), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12...

Full description

Bibliographic Details
Main Authors: Chionne Paola, Rapicetta Maria, Oddone Maurizio, Zito Salvatore, Marchisio Maria, Montù Domenico, Barale Antonella, Bella Antonino, Giambi Cristina, Madonna Elisabetta, Atti Marta
Format: Article
Language:English
Published: BMC 2008-07-01
Series:BMC Infectious Diseases
Online Access:http://www.biomedcentral.com/1471-2334/8/100
id doaj-03edfaafed334dfd9b73811b3928d991
record_format Article
spelling doaj-03edfaafed334dfd9b73811b3928d9912020-11-25T03:40:11ZengBMCBMC Infectious Diseases1471-23342008-07-018110010.1186/1471-2334-8-100A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccinesChionne PaolaRapicetta MariaOddone MaurizioZito SalvatoreMarchisio MariaMontù DomenicoBarale AntonellaBella AntoninoGiambi CristinaMadonna ElisabettaAtti Marta<p>Abstract</p> <p>Background</p> <p>In 2001, two hexavalent vaccines were licensed in Italy (Hexavac<sup>®</sup>, Infanrix Hexa<sup>®</sup>), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac<sup>® </sup>was precautionary suspended by EMEA, because of doubts on long-term protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine.</p> <p>Methods</p> <p>Participant children were enrolled concomitantly with the offering of anti-polio booster dose, in the third year of life. Anti-HBs titers were determined on capillary blood samples. A booster dose of hepatitis B vaccine was administered to children with anti-HBs titers < 10 mIU/ml, with the monovalent precursor product of the previously received hexavalent vaccine. HBsAb titers were tested again one month after the booster.</p> <p>Results</p> <p>Sera from 113 children previously vaccinated with Hexavac<sup>®</sup>, and from 124 vaccinated with Infanrix Hexa<sup>® </sup>were tested for anti-HBs. Titers were ≥ 10 mIU/ml in 69% and 96% (p < 0,0001) respectively. The proportion of children with titers ≥ 100 mIU/ml did also significantly differ among groups (27% and 78%; p < 0,0001).</p> <p>Post-booster, 93% of children achieved titers ≥ 10 mIU/ml, with no significant difference by vaccine group.</p> <p>Discussion</p> <p>Fifteen months after third dose administration, a significant difference in anti-HBs titers was noted in the two vaccine groups considered. Monovalent hepatitis B vaccine administration in 3-year old children induced a proper booster response, confirming that immunologic memory persists in children with anti-HBs titers < 10 mIU/ml. However, long-term persistence of HBV protection after hexavalent vaccines administration should be further evaluated over time.</p> http://www.biomedcentral.com/1471-2334/8/100
collection DOAJ
language English
format Article
sources DOAJ
author Chionne Paola
Rapicetta Maria
Oddone Maurizio
Zito Salvatore
Marchisio Maria
Montù Domenico
Barale Antonella
Bella Antonino
Giambi Cristina
Madonna Elisabetta
Atti Marta
spellingShingle Chionne Paola
Rapicetta Maria
Oddone Maurizio
Zito Salvatore
Marchisio Maria
Montù Domenico
Barale Antonella
Bella Antonino
Giambi Cristina
Madonna Elisabetta
Atti Marta
A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
BMC Infectious Diseases
author_facet Chionne Paola
Rapicetta Maria
Oddone Maurizio
Zito Salvatore
Marchisio Maria
Montù Domenico
Barale Antonella
Bella Antonino
Giambi Cristina
Madonna Elisabetta
Atti Marta
author_sort Chionne Paola
title A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
title_short A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
title_full A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
title_fullStr A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
title_full_unstemmed A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
title_sort cohort study to evaluate persistence of hepatitis b immunogenicity after administration of hexavalent vaccines
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2008-07-01
description <p>Abstract</p> <p>Background</p> <p>In 2001, two hexavalent vaccines were licensed in Italy (Hexavac<sup>®</sup>, Infanrix Hexa<sup>®</sup>), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac<sup>® </sup>was precautionary suspended by EMEA, because of doubts on long-term protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine.</p> <p>Methods</p> <p>Participant children were enrolled concomitantly with the offering of anti-polio booster dose, in the third year of life. Anti-HBs titers were determined on capillary blood samples. A booster dose of hepatitis B vaccine was administered to children with anti-HBs titers < 10 mIU/ml, with the monovalent precursor product of the previously received hexavalent vaccine. HBsAb titers were tested again one month after the booster.</p> <p>Results</p> <p>Sera from 113 children previously vaccinated with Hexavac<sup>®</sup>, and from 124 vaccinated with Infanrix Hexa<sup>® </sup>were tested for anti-HBs. Titers were ≥ 10 mIU/ml in 69% and 96% (p < 0,0001) respectively. The proportion of children with titers ≥ 100 mIU/ml did also significantly differ among groups (27% and 78%; p < 0,0001).</p> <p>Post-booster, 93% of children achieved titers ≥ 10 mIU/ml, with no significant difference by vaccine group.</p> <p>Discussion</p> <p>Fifteen months after third dose administration, a significant difference in anti-HBs titers was noted in the two vaccine groups considered. Monovalent hepatitis B vaccine administration in 3-year old children induced a proper booster response, confirming that immunologic memory persists in children with anti-HBs titers < 10 mIU/ml. However, long-term persistence of HBV protection after hexavalent vaccines administration should be further evaluated over time.</p>
url http://www.biomedcentral.com/1471-2334/8/100
work_keys_str_mv AT chionnepaola acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT rapicettamaria acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT oddonemaurizio acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT zitosalvatore acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT marchisiomaria acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT montudomenico acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT baraleantonella acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT bellaantonino acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT giambicristina acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT madonnaelisabetta acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT attimarta acohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT chionnepaola cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT rapicettamaria cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT oddonemaurizio cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT zitosalvatore cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT marchisiomaria cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT montudomenico cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT baraleantonella cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT bellaantonino cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT giambicristina cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT madonnaelisabetta cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
AT attimarta cohortstudytoevaluatepersistenceofhepatitisbimmunogenicityafteradministrationofhexavalentvaccines
_version_ 1724535687089225728